glutathione rapta c Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib Dichloro Ru(II)-p-cymene-1,3,5-triaza-7-phosphaadamantane (RAPTA-C): A Case
Dichloro Ru(II) p cymene 1,3,5 triaza 7 phosphaadamantane (RAPTA C): A Case Study ACS Pharmacology & Translational Science Synthesis, characterizacion and study of novel heterobimetallic RAPTA type Ru(II) complexes ScienceDirect Integrative Therapeutics Glutathione Cell Defense Combinative Treatment of the PARP Inhibitor Olaparib and Antimetastasis Ruthenium(II)Arene Compound RAPTA T for Triple Negative BRCA1 Wild Type Breast Cancer Cells
Pay in 4 interest-free payments of $5.13 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 14 - Sep 19



